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Abstract The peroxisome proliferator-activated receptor K
(PPARK) is a transcription factor belonging to the PPAR
subfamily of nuclear receptors. Fatty acids and eicosanoids are
natural PPARK ligands. Here, we show using transient
transfection assays that oxidized (oxLDL) but not native low-
density lipoproteins (LDL) dose-dependently activate PPARK in
endothelial cells without affecting PPARK protein expression.
Fractioning of oxLDL lipids followed by transactivation
experiments demonstrated that the oxidized phospholipid com-
ponent in oxLDL is responsible for PPARK activation. Using
specific inhibitors, it is shown that oxLDL-mediated PPARK
activation requires phospholipase A2 activity and that the
oxidized fatty acids 9- and 13-HODE activate PPARK directly.
Finally, we found that, similar to the synthetic PPARK ligand
Wy-14643, oxLDL induced expression of the fatty acid transport
protein-1 in human primary endothelial cells. Our findings define
a novel group of PPARK activators and provide a molecular
basis for certain effects of these biologically active phospholipids
on gene transcription.
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1. Introduction
Peroxisome proliferator-activated receptors (PPARs) are li-
gand-activated transcription factors which belong to the nu-
clear receptor superfamily [1]. Three di¡erent PPAR subtypes
have been identi¢ed to date: PPARK, PPARN and PPARQ.
PPARK and PPARQ are the best characterized PPARs. PPARK
stimulates the L-oxidative degradation of fatty acids whereas
PPARQ promotes lipid storage via its e¡ects on adipocyte
di¡erentiation and function (see [2] for review). Recently,
PPARK and PPARQ have also been shown to play a role in
in£ammatory control (see [2,3] for review).
PPARs regulate gene expression by binding with the 9-cis-
retinoid X receptor (RXR) as heterodimeric partner to speci¢c
DNA sequence elements termed PPAR response elements
(PPRE) [4]. In addition, PPARs regulate gene transcription
in a DNA binding-independent manner by negatively interfer-
ing with the AP-1 and NF-UB transcriptional activities [5].
The lipid-lowering ¢brates and the anti-diabetic glitazones
are synthetic ligands for, respectively, PPARK and PPARQ
[6,7]. Long chain fatty acids such as linoleic, linolenic and
arachidonic acid [6,8^10] have been identi¢ed as natural
PPAR activators which bind and activate both PPARK and
PPARQ. PPARs are furthermore activated by fatty acid deriv-
atives. A cyclooxygenase product of arachidonic acid, 15d-
v12,14-PGJ2, has been identi¢ed as a selective PPARQ ligand
[11,12] whereas its lipoxygenase product, 8(S)-hydroxy-
(5Z,9E,11Z,14Z)-eicosatetraenoic acid (HETE), is a stereose-
lective PPARK agonist [6,8,9]. Moreover, Devchand et al. [13]
showed that the pro-in£ammatory arachidonic-acid deriva-
tive, LTB4, is a PPARK ligand. Recently, it has been shown
that oxidized low-density lipoproteins (oxLDL) regulate mac-
rophage gene expression through ligand activation of PPARQ
[14]. By screening oxidized sterols and fatty acids contained in
the oxLDL particle, Nagy et al. identi¢ed two oxidized me-
tabolites of linoleic acid, 9- and 13-hydroxyoctadecadienoic
acid (9-HODE and 13-HODE), as potent PPARQ activators
[14]. Finally, Huang et al. found that interleukin-4 (IL-4)-in-
duced PPARQ activity in macrophages requires the 12/15
lipoxygenase pathway which catalyzes the conversion of ara-
chidonic acid and linoleic acid to generate the PPARQ ligands
15-HETE and 13-HODE, respectively [15]. However, to date
it is unknown whether any of these oxLDL-derived fatty acids
also a¡ect PPARK activity.
The aim of this study was therefore to determine the e¡ects
of oxLDL on PPARK activity in human endothelial cells
which express high levels of PPARK compared to PPARQ
[16]. Our results of transient transfections demonstrate that
oxLDL induce PPARK activity in a dose-dependent manner
without a¡ecting its protein expression. Furthermore, by LDL
lipid fractioning, oxidized phospholipids were identi¢ed as
PPARK activators. Using speci¢c inhibitors it was demon-
strated that phospholipase A2 (PLA2) but not lipoxygenases
nor cyclooxygenases are required for this activation. More-
over, 9- and 13-HODE were found to activate PPARK in
transient transfection experiments. Finally, we demonstrate
that oxLDL, as well as the synthetic PPARK ligand Wy-
14643, regulate the expression of the PPAR target gene, fatty
acid transport protein-1 (FATP-1), in human primary endo-
thelial cells.
2. Materials and methods
2.1. Cell culture and chemical reagents
Human coronary artery endothelial cells (CAEC) (Clonetics), cul-
tured in endothelial cell basal medium supplemented with 5% fetal
calf serum (FCS) and various growth factors as described by the
0014-5793 / 00 / $20.00 ß 2000 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 0 ) 0 1 3 6 4 - 8
*Corresponding author. Fax: (33)-3-20 87 73 60.
E-mail: bart.staels@pasteur-lille.fr
FEBS 23502 30-3-00
FEBS 23502FEBS Letters 471 (2000) 34^38
manufacturer, were used for RNA and Western blot analysis. Murine
aortic endothelial cells (MAE) (ATCC, Rockville, MD, USA), cul-
tured in Dulbecco’s modi¢ed Eagle’s medium supplemented with
10% FCS, 600 ng/ml glutamine, 100 U/ml penicillin and 100 Wg/ml
streptomycin, were used for the transient transfection experiments.
Nordihydroguaiaretic acid (NDGA) and 1-palmitoyl-2-arachidono-
yl-sn-glycero-3-phosphocholine (PAPC) were provided by Sigma,
Saint-Quentin, France. Ketoprofen was from Rho“ne-Poulenc Rorer,
Vitry, France. Arachidonyltri£uoromethyl ketone (AACOCF3) was
from Euromedex, Strasbourg, France and 9- and 13-HODE were
from Cayman Research. The goat polyclonal PPARK antibody was
from Research Diagnostics, Flanders, NJ, USA.
2.2. Protein extraction and Western blot analysis
CAEC cells were washed twice in ice cold phosphate bu¡ered saline
(PBS) and harvested in ice cold lysis bu¡er containing PBS, 1% Triton
X-100 and a freshly prepared protease inhibitor cocktail (ICN, Orsay,
France) (10 mg/ml 4-(2-aminoethyl)-benzenesulphonyl £uoride
(AEBSF), 1 mg/ml leupeptin, 1 mg/ml pepstatin, 5 mg/ml EDTA-
Na2) to which 1 mM phenylmethylsulfonyl £uoride was added. Cell
homogenates were collected by centrifugation at 13 000 rpm at 4‡C.
Protein concentrations were determined using the bicinchoninic acid
assay (Pierce Interchim, Montlucon, France). Electrophoresis of the
indicated amount of protein lysate was performed through a 10%
polyacrylamide gel under reducing conditions (sample bu¡er contain-
ing 10 mM dithiothreitol). Proteins were transferred onto nitrocellu-
lose membranes and membranes were checked for equal loading by
Ponceau red staining. Non-speci¢c binding sites were blocked over-
night at 4‡C with 10% skim milk powder in TBST (20 mM Tris^HCl,
55 mM NaCl, 0.1% Tween 20). Membranes were subsequently incu-
bated for 4 h at room temperature in 5% skim milk^TBST containing
a goat polyclonal PPARK antibody. After incubation with a second-
ary peroxidase conjugated antibody, signals were visualized by chem-
iluminescence (Amersham, Buckinghamshire, UK).
2.3. RNA analysis
RNA preparation and Northern blot hybridizations were per-
formed as previously described [17]. FATP-1 [18] and 36B4 cDNA
fragments were used as probes.
2.4. Lipoprotein isolation and oxidation
LDLs (d = 1.03^1.053) were isolated from freshly drawn blood from
healthy normolipidemic volunteers, dialyzed, sterilized and stored at
4‡C as previously described [19]. The protein concentration was de-
termined by using Peterson’s method with bovine serum albumin as
standard. LDLs (1 mg protein/ml) were oxidized with 1.66 mM
CuSO4 at 37‡C for 24 h. Native and oxLDL were screened for lipo-
polysaccharide (LPS) contamination by using a limulus lysate assay.
All the di¡erent LDL preparations used in this study contained less
than 0.75 IU of LPS/ml. LDL contained 20 þ 4 nmol peroxides/mg
protein and 0.163 nmol TBARS (thiobarbituric acid-reactive substan-
ces)/mg protein whereas oxLDL contained 215.2 þ 32 nmol peroxides/
mg protein and 46 þ 4 nmol TBARS/mg protein.
2.5. Lipid extraction
Total lipid extracts of 1 ml of native or oxLDL (1 mg protein/ml)
were extracted with 2 ml of CHCl3^MeOH (2:1, v/v) containing
0.01% butylated hydroxytoluene, the pooled organic fractions were
evaporated to dryness under nitrogen and the residue was dissolved
in 100 Wl of MeOH (for use on cells) or in 100 Wl of hexane for further
separation. Fractionation of the total lipid extract in hexane was
accomplished with Bakerbond spe Diol (Baker) extraction columns
(3 ml) preconditioned by washing with hexane (5 ml) [20,21]. The
column was eluted with 2 ml of increasingly polar solvent mixtures
to give eight fractions: fraction 1, 1% ethyl acetate in hexane; fraction
2, 5% ethyl acetate in hexane; fraction 3, 15% ethyl acetate in hexane;
fraction 4, 30% ethyl acetate in hexane; fraction 5, 60% ethyl acetate
in hexane; fraction 6, 100% ethyl acetate; fraction 7, 30% MeOH in
CH2Cl2 and fraction 8, 100% MeOH. The eluates were evaporated to
dryness and reconstituted in 100 Wl of MeOH. Fraction 1 contained
esteri¢ed cholesterol, fraction 4 triglycerides and free cholesterol and
fraction 7 phospholipids. In some studies, LDL solutions were re-
duced with sodium borohydride (10 mg) [22], the samples were kept
on ice for 20 min and then at room temperature for a further 100 min.
At this time, 20 Wl glacial acetic acid was added followed by 1 ml
water. The non-reduced samples were subjected to the same condi-
tions except that sodium borohydride was omitted. Oxidized PAPC
(oxPAPC) was obtained by transferring 1 mg PAPC in 100 Wl of
chloroform and evaporating the solvent under a stream of nitrogen.
The lipid residue was allowed to autoxidize on exposure to air for
48 h.
2.6. Plasmids and transient transfection assays
The plasmids pGal5-TK-pGL3, J6-TK-pGL3, Gal4-hPPARK and
pSG5-hPPARK have been previously described [5]. MAE cells, grown
in 24-well plates to 50^60% con£uence in DMEM supplemented with
10% FCS, were transiently transfected using a lipid cationic technique
(RPR120535B, Rho“ne-Poulenc Rorer, Vitry, France) with reporter
and expression plasmids, as stated in the ¢gure legends. Phosphogly-
cerate kinase (PGK) L-galactosidase expression plasmid (50 ng) was
cotransfected as a control for transfection e⁄ciency. Two hours post-
transfection, the medium was refreshed and supplemented with the
various PPAR activators as stated in the ¢gure legends. After 48 h,
cells were collected and the luciferase and L-galactosidase assays were
performed as previously described [5]. Reporter gene activity is pre-
sented as fold induction over vehicle control. All the experiments were
performed at least three times.
2.7. Cell viability assay
Cell viability was determined by using the Celltiter 96 Aqueous one
solution cell proliferation assay (Promega, Charbonnie'res, France)
based on the bioreduction of a tetrazolium compound (MTS) into a
colored formazan product. The quantity of formazan product meas-
ured at 490 nm is directly proportional to the number of living cells.
3. Results
3.1. oxLDL activate PPARK in a dose-dependent manner
To determine whether oxLDL modulate PPARK-dependent
transcription, MAE cells were transfected with a multiple
PPRE-driven promoter construct in the presence or absence
of PPARK and RXRK (Fig. 1A). In the absence of cotrans-
fected PPARK, LDL and oxLDL (100 Wg/ml) did not in£u-
ence PPRE-driven reporter activity which is consistent with
the absence of endogenous PPARK in MAE cells (data not
shown). Cotransfection of PPARK led to a two-fold increase
of basal promoter activity which was not a¡ected by LDL
treatment. oxLDL incubation resulted in a signi¢cant (sev-
en-fold) increase of the promoter activity. Cotransfection of
both PPARK and RXRK led to a drastic induction (almost
30-fold) of reporter activity. LDL failed to activate the
Fig. 1. oxLDL activate PPARK in a dose-dependent manner. A:
MAE cells were transfected with J6-TK-pGL3 (100 ng) in the pres-
ence of hPPARK (30 ng) and RXRK (30 ng) or empty (pSG5) ex-
pression plasmids as described in Section 2. After transfection, cells
were refed with DMEM supplemented with 0.2% FCS in the pres-
ence of LDL or oxLDL (100 Wg/ml) or vehicle (PBS) for 36 h.
B: MAE cells were transfected with the pGal5-TK-pGL3 reporter
(100 ng) and Gal4-hPPARK expression plasmids (20 ng). After
transfection, cells were refed with DMEM supplemented with 0.2%
FCS in the presence of increasing concentrations oxLDL (0^100 Wg/
ml) for 36 h.
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PPARK^RXRK heterodimer whereas incubation with oxLDL
resulted in a further induction of reporter activity (Fig. 1A).
In a second set of experiments, the in£uence of oxLDL was
tested on a chimeric construct comprising the DNA binding
domain of the Gal4 yeast transcription factor fused to the
ligand binding domain of PPARK. This system is completely
independent of endogenous RXR. Incubation of MAE cells
with increasing concentrations of oxLDL resulted in a dose-
dependent increase of Gal4-driven promoter activity (25-fold
with 100 Wg/ml) (Fig. 1B). As a control, native LDL at similar
concentrations failed to activate this promoter construct (not
shown). These results indicate that oxLDL activates PPARK-
dependent transcription in a dose-dependent manner in MAE
cells.
3.2. Oxidized phospholipids activate PPARK-dependent
transcription
In order to identify which chemical components of the
oxLDL particle are involved in PPARK activation, total lipids
from LDL and oxLDL were extracted and tested in the trans-
activation assays. First, it was demonstrated that the protein
moiety is unable to activate PPARK (data not shown). There-
fore, bonded phase columns were used to separate the di¡er-
ent classes of lipids in oxLDL. When the Gal4-chimeric/re-
porter system was used to test the e¡ect of these di¡erent lipid
components, unoxidized triglycerides, cholesteryl esters and
phospholipids were not found to transactivate the PPARK
chimera (Fig. 2A). By contrast, oxidized phospholipids signif-
icantly activated PPARK-driven transcription (almost eight-
fold) albeit to a lesser extent compared to entire oxLDL
(11-fold) (Fig. 2A). Oxidized cholesteryl esters and triglycer-
ides did not activate PPARK. Since it has been reported that
oxidation products of PAPC mediate the action of oxidized
LDL on endothelial cells [23], the in£uence of PAPC and
oxPAPC on PPARK-dependent transcription was further
tested. oxPAPC treatment in MAE cells resulted in a dose-
dependent induction of the PPRE-driven promoter activity
whereas PAPC, even when tested at high concentrations,
had almost no e¡ect (Fig. 2B). These results suggest that
oxidized phospholipids mediate oxLDL-induced PPARK acti-
vation in MAE cells.
3.3. PLA2 is required for oxLDL-mediated PPARK
transactivation
To determine whether oxLDL-derived lipids require intra-
cellular modi¢cations to activate PPARK, their e¡ects on
PPARK transactivation were further studied in the presence
of speci¢c inhibitors of cyclooxygenase (ketoprofen), lipoxy-
genase (NDGA) and PLA2 (AACOCF3). Incubation of
oxLDL (50 Wg/ml) led to a strong activation of the chimeric
Gal4-PPARK/reporter system (13-fold) which was not signi¢-
cantly a¡ected by pretreatment (3 h) with cyclooxygenase nor
lipoxygenase inhibitors (Fig. 3A). Interestingly, the speci¢c
PLA2 inhibitor (AACOCF3) reduced signi¢cantly oxLDL-in-
duced promoter activation (Fig. 3A). During these experi-
ments, cell viability was determined using a 3-[4,5-dimethyl-
thiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT)-derived
assay. Incubation for 3 h with the various inhibitors did not
lead to a reduced cell viability suggesting that the e¡ect of the
Fig. 2. Oxidized phospholipids activate PPARK. A: MAE cells were
transfected with the pGal5-TK-pGL3 reporter (100 ng) and Gal4-
hPPARK expression (20 ng) plasmids. After transfection, cells were
refed with DMEM supplemented with 0.2% FCS and the indicated
lipid fractions (equivalent to 50 Wg/ml LDL) (CE: cholesteryl esters;
TG: triglycerides; PL: phospholipids), LDL and oxLDL (50 Wg/ml)
for 36 h. B: MAE cells were transfected with J6-TK-pGL3 (100 ng)
in the presence of hPPARK (30 ng). After transfection, cells were
refed with DMEM supplemented with 0.2% FCS in the presence of
increasing concentrations of PAPC or oxPAPC (2.5^10 Wg/ml) for
36 h.
Fig. 3. PLA2 is required for oxLDL-mediated PPARK transactiva-
tion. A: MAE cells were transfected with pGal5-TK-pGL3 (100 ng)
and Gal4-hPPARK (20 ng). 12 h after transfection, cells were pre-
treated with ketoprofen (100 WM), NDGA (10 WM), AACOCF3
(10 WM) or solvent (0.1% ethanol) for 3 h and subsequently refed
with DMEM supplemented with 0.2% FCS and LDL or oxLDL
(50 Wg/ml) for 24 h. B: MAE cells were transfected as described in
(A). After transfection, cells were refed with DMEM supplemented
with 0.2% FCS in the presence of 9- or 13-HODE (30 WM) or Wy-
14643 (50 WM) or solvent (0.1% ethanol).
Fig. 4. oxLDL induce the PPARK target gene FATP-1 in CAEC
cells without a¡ecting PPARK protein expression. A: CAEC cells
were incubated for 24 h in standard medium supplemented with
LDL or oxLDL (100 Wg/ml) or Wy-14643 (50 WM) or vehicle
(DMSO 0.1%). FATP-1 and 36B4 mRNA were measured by North-
ern blot analysis. FATP-1 mRNA levels were quanti¢ed and nor-
malized to 36B4 mRNA levels by densitometric analysis. The results
of three di¡erent experiments are expressed in relative arbitrary
units (R.A.U.) (B). C: CAEC were cultured for 24 h similarly as
described in A. Total protein extracts were prepared and proteins
(50 Wg) were separated by SDS^PAGE, transferred to a Hybond
membrane and probed with a polyclonal PPARK antibody.
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PLA2 inhibitor is not due to cytotoxicity (data not shown).
This experiment indicates that PLA2 is required for oxLDL-
stimulated PPARK activation in endothelial cells. Since it has
been demonstrated that hydrolysis of oxidized phospholipids
by PLA2 may produce biologically active oxidized fatty acids
[24] and since 9- and 13-HODE have been identi¢ed as po-
tential PPARQ ligands [14], we tested the in£uence of these
compounds on PPARK-mediated transactivation. 9- and 13-
HODE activated 25- and 10-fold the Gal4-driven promoter
activity in the presence of cotransfected PPARK chimera, re-
spectively (Fig. 3B). As a control, the synthetic PPARK ago-
nist Wy-14643 drastically activated the reporter construct.
Taken together, these data demonstrate that 9- and 13-
HODE are PPARK activators as similarly reported for PPARQ
[14].
3.4. oxLDL regulate FATP gene expression in CAEC cells
To determine whether oxLDL could also activate PPARK
in endothelial cells in vivo, the in£uence of oxLDL on known
PPARK target gene expression was tested in CAEC cells and
compared to those of the PPARK ligand Wy-14643. The fatty
acid transporter/scavenger receptor CD36/FAT has been re-
ported to be a PPAR-responsive gene [25,26] whose expres-
sion is regulated by oxLDL in macrophages [26]. Unfortu-
nately, Northern blot analysis failed to detect CD36/FAT
mRNA in CAEC cells. Therefore, the e¡ect of oxLDL and
Wy-14643 was studied on FATP-1 which is ubiquitously ex-
pressed and is positively regulated by PPAR activators [18,25].
Untreated CAEC cells exhibit a basal FATP-1 mRNA level
which was signi¢cantly increased by Wy-14643 treatment (Fig.
4A). Incubation of CAEC cells with oxLDL (100 Wg/ml) but
not with LDL resulted also in a signi¢cant induction of
FATP-1 mRNA (Fig. 4A). These data suggest that oxLDL
regulate FATP-1 gene expression in endothelial cells via
PPARK activation. Since it has been reported that oxLDL
induce PPARQ expression in macrophages [26], we tested the
in£uence of LDL and oxLDL (100 Wg/ml) for 24 h on PPARK
protein expression in primary human CAEC. Neither LDL
nor oxLDL modi¢ed PPARK protein (Fig. 4C) nor mRNA
(data not shown) levels in CAEC indicating that oxLDL reg-
ulate FATP-1 gene expression without altering PPARK pro-
tein expression.
4. Discussion
In this study, it is shown, for the ¢rst time, that oxLDL but
not native LDL activate PPARK in a PLA2-dependent man-
ner. Furthermore, oxLDL incubation resulted in the induction
of the well-characterized PPARK target gene, FATP-1. This
induction by oxLDL was similar as the one obtained using the
synthetic PPARK ligand Wy-14643 in primary CAEC cells. In
contrast to the previously reported induction of PPARQ ex-
pression in macrophages [26], oxLDL treatment of endothelial
cells did not in£uence PPARK protein expression levels.
Using transient transfection assays, it was found that
oxLDL but not native LDL provide PPARK activators to
endothelial cells. Thus, as similarly reported for PPARQ in
macrophages, the ability of LDL and oxLDL to activate
PPARK is directly related to the oxidation state of the particle
[14]. The mechanism by which endothelial cells take up the
oxLDL or their components to generate endogenous PPARK
activators, remains largely unknown. Nagy et al. [14] reported
that PPARQ-dependent gene regulation by oxLDL in macro-
phages is mediated via the CD36/FAT scavenger receptor.
However, CD36/FAT expression was undetectable in CAEC
cells thereby excluding a role for this receptor in oxLDL up-
take in endothelial cells. However, it is possible that endothe-
lial cells take up oxLDL via the lectin-like oxidized LDL
receptor-1 (LOX-1) which is highly expressed in human
CAEC cells [27] and displays a high a⁄nity for oxLDL [28].
Further studies will be required to delineate more precisely
whether oxLDL-induced PPARK activation occurs via this
mechanism.
The experiments using isolated lipid fractions of oxLDL led
us to identify oxidized phospholipids as natural PPARK acti-
vators in endothelial cells. The fact that a speci¢c PLA2 in-
hibitor can blunt oxLDL-induced PPARK activation, suggests
that oxidized phospholipids are not PPARK ligands per se but
are precursors for the true endogenously generated activators.
PLA2 belongs to a family of signal transduction enzymes
which catalyze fatty acid hydrolysis from the sn-2 position
of phospholipids with concomitant production of lysophos-
pholipids [29]. Cleavage of oxidized phospholipids by PLA2
leads to the release of oxidized fatty acids, such as oxidized-
arachidonic or oxidized-linoleic acid. Chatidis et al. demon-
strated that PLA2 is able to liberate 15-HETE from 15-lip-
oxygenated PAPC [24]. It is therefore likely that the PPAR
ligands 9- and 13-HODE or 15-HETE may be produced by
such hydrolysis of oxLDL-derived phospholipids. Our results
demonstrate that 9- and 13-HODE are not only PPARQ but
also PPARK activators suggesting that oxidized fatty acids
might be responsible for PPARK activation by oxLDL. Using
PLA2-speci¢c inhibitors, Couturier et al. demonstrated that
PLA2 is involved in IL-1-mediated sPLA2 gene induction in
rat aortic smooth muscle cells [30]. They found that IL-1-
activated PLA2 liberates fatty acids which are oxidized by
lipoxygenases leading to the formation of PPARQ ligands
such as 15-HETE, 9- and 13-HODE [30]. Their data and
our results emphasize the role of PLA2 as one of the ¢rst
steps involved in the generation of PPAR ligands in endothe-
lial cells and smooth muscle cells. In addition, in a recent
paper, Huang et al. found that IL-4-induced CD36/FAT ex-
pression in macrophages requires the 12/15 lipoxygenase
which catalyzes the conversion of arachidonic acid and lino-
leic acid to 15-HETE and 13-HODE, respectively [15], thus
resulting in the generation of PPARQ ligands. Altogether these
reports indicate that natural PPARK and PPARQ activators
may be generated by various complex pathways in di¡erent
cells.
Oxidative stress is one of the main regulators of gene ex-
pression in the vasculature (see [31] for review). The role of
oxLDL as an important oxidative signal in the pathogenesis
of atherosclerosis has been well established [32]. oxLDL act
by activating the redox-sensitive transcription factors AP-1
[33] and NF-UB [34] which drive the transcription of numer-
ous genes involved in atherogenesis such as VCAM-1, MCP-1,
etc. However, several reports demonstrated that oxLDL as
well as oxidized phospholipids may also exert anti-in£amma-
tory properties at the level of the vascular wall. Leitinger et al.
demonstrated that oxPAPC dose-dependently inhibit LPS-in-
duced neutrophil binding and E-selectin expression at the
transcriptional level in endothelial cells [35]. Eligini et al.
found that oxLDL-mediated inhibition of LPS-induced
COX-2 expression in macrophages was mimicked by oxPAPC
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[36]. We and others demonstrated that PPARK activators
negatively regulate the vascular in£ammatory response by re-
ducing COX-2 [37], IL-6 [5] and VCAM-1 [38] in vascular
cells. Based on these di¡erent observations, it is tempting to
speculate that the anti-in£ammatory activities of oxidized
phospholipids and oxLDL are PPARK-mediated. Further
studies are required to elucidate this question.
In addition, PPARK was reported to play a major role in
the control of the cellular redox status [39,40]. Klucis et al.
reported that administration of PPARK activators results in a
drastic increase of the hepatic activity of catalase, an anti-
oxidant enzyme [41]. It will be of interest to determine
whether catalase may be induced by synthetic (¢brates) or
natural ligands such as oxidized phospholipids in endothelial
cells. This might contribute to a decrease of the cellular oxi-
dative stress and therefore to a decrease of the NF-UB and
AP-1 activities. Since PPARK has been proposed as a modu-
lator of the in£ammatory response and of the cellular redox
status, the pro-in£ammatory activities of oxLDL should thus
be balanced by PPARK activation. The equilibrium of both
oxLDL actions will therefore determine the in£ammatory
phenotype of the cell.
In conclusion, our data clearly show that oxLDL and oxi-
dized phospholipids activate PPARK in endothelial cells in a
PLA2-dependent manner. Moreover, oxLDL treatment re-
sulted in the induction of FATP-1 gene expression in endo-
thelial cells probably via PPARK activation. These results
provide a possible molecular mechanism of anti-in£ammatory
action of certain oxLDL components in endothelial cells.
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